Insider Financial sent our subscribers a full research report on Hilstream Biopharma Inc (NASDAQ: HILS) on February 3. It opened at 1.17 and had an average trade on the session of 1.10. On Friday, the company released some explosive news that you can read on their news feed. The Street loved the news and responded by sending this to $2.65 on massive record interest. HILS had a coming-out party and is now on the screens of tens of thousands of traders that had no idea about it yesterday, except for our subscribers. If you caught any piece of that 5-day, 140% run on huge interest, then congrats are certainly to you.
Our full HILS report: https://insiderfinancial.com/hils1/
Sign up here for our FREE real-time reports and eBook.
Stocks covered in this video include SPY, QQQ, HILS, PLTR, CAR, MNDY, ABNB, MAR, UPST, GP, ARKK, CSCO, SHOP, RBLX, ROKU, DKNG, DE, AN, CVNA, TSLA, HPCO, GTII, GNS, XPON, and LYFT.
As we keep saying, there are always opportunities in the markets, and it’s our job to find winning stocks to buy. Huge gains can be made in such a short amount of time.
It’s essential to look for penny stocks that have yet to run. There are plenty of opportunities, and we look at hundreds of penny stocks weekly for our subscribers.
Remember, all it takes is one or two to become a winner, and you’ve crushed the market indices (and Jim Cramer) for the year.
Good luck to all (except the shorts and Cramer)!
WHEN INSIDER FINANCIAL HAS A STOCK REPORT, IT CAN PAY TO LISTEN. AFTER ALL, OUR FREE NEWSLETTER HAS FOUND MANY TRIPLE-DIGIT WINNERS FOR OUR SUBSCRIBERS. WE SPECIALIZE IN FINDING MOMENTUM BEFORE IT HAPPENS!
Disclosure: We have not been compensated for this article/video. Insider Financial is not an investment advisor; this article/video does not provide investment advice. Always do your research, make your own investment decisions, or consult with your nearest financial advisor. This article/video is not a solicitation or recommendation to buy, sell, or hold securities. This article/video is our opinion, is meant for informational and educational purposes only, and does not provide investment advice. Past performance is not indicative of future performance.